|
Name |
Sydowic acid, (+)-
|
Molecular Formula | C15H20O4 | |
IUPAC Name* |
3-hydroxy-4-[(2R)-2,6,6-trimethyloxan-2-yl]benzoic acid
|
|
SMILES |
C[C@@]1(CCCC(O1)(C)C)C2=C(C=C(C=C2)C(=O)O)O
|
|
InChI |
InChI=1S/C15H20O4/c1-14(2)7-4-8-15(3,19-14)11-6-5-10(13(17)18)9-12(11)16/h5-6,9,16H,4,7-8H2,1-3H3,(H,17,18)/t15-/m1/s1
|
|
InChIKey |
PPKSRWBBMMEDGG-OAHLLOKOSA-N
|
|
Synonyms |
Sydowic acid, (R)-; Sydowic acid, (+)-; 8UAK634V59; 3-Hydroxy-4-((2R)-tetrahydro-2,6,6-trimethyl-2H-pyran-2-yl)benzoic acid; Benzoic acid, 3-hydroxy-4-((2R)-tetrahydro-2,6,6-trimethyl-2H-pyran-2-yl)-; Benzoic acid, 3-hydroxy-4-(tetrahydro-2,6,6-trimethyl-2H-pyran-2-yl)-, (R)-; 120442-16-2; (+)-Sydowic acid; R)-(+)-sydowic acid; (R)-(+)-sydowic acid; UNII-8UAK634V59; CHEMBL4519267
|
|
CAS | 120442-16-2 | |
PubChem CID | 11737144 | |
ChEMBL ID | CHEMBL4519267 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 264.32 | ALogp: | 2.4 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.845 |
Caco-2 Permeability: | -4.804 | MDCK Permeability: | 0.00002190 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.018 |
Blood-Brain-Barrier Penetration (BBB): | 0.062 | Plasma Protein Binding (PPB): | 89.83% |
Volume Distribution (VD): | 0.475 | Fu: | 12.24% |
CYP1A2-inhibitor: | 0.033 | CYP1A2-substrate: | 0.804 |
CYP2C19-inhibitor: | 0.042 | CYP2C19-substrate: | 0.066 |
CYP2C9-inhibitor: | 0.201 | CYP2C9-substrate: | 0.27 |
CYP2D6-inhibitor: | 0.02 | CYP2D6-substrate: | 0.118 |
CYP3A4-inhibitor: | 0.053 | CYP3A4-substrate: | 0.125 |
Clearance (CL): | 3.159 | Half-life (T1/2): | 0.874 |
hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.373 |
Drug-inuced Liver Injury (DILI): | 0.942 | AMES Toxicity: | 0.014 |
Rat Oral Acute Toxicity: | 0.056 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.118 | Carcinogencity: | 0.063 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.811 |
Respiratory Toxicity: | 0.028 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002280 | 1.000 | D0N0RU | 0.344 | ||||
ENC005925 | 0.695 | D0C4YC | 0.290 | ||||
ENC004192 | 0.609 | D01CKY | 0.290 | ||||
ENC004190 | 0.569 | D01WJL | 0.290 | ||||
ENC004186 | 0.565 | D0D0GV | 0.272 | ||||
ENC004350 | 0.431 | D07HBX | 0.258 | ||||
ENC000002 | 0.404 | D0W6DG | 0.253 | ||||
ENC000296 | 0.383 | D04BCW | 0.253 | ||||
ENC001626 | 0.373 | D03XES | 0.250 | ||||
ENC001090 | 0.358 | D0BA6T | 0.250 |